Overview

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Status:
Recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
Phase:
Phase 3
Details
Lead Sponsor:
Zenas BioPharma (USA), LLC